[Analysis of Related Factors of Survival and Prognosis in Patients With High-risk Refractory Lymphoma Treated with Auto-PBHSCT].

OBJECTIVE: To analyze the factors affecting survival and prognosis of patients with high-risk refractory lymphoma treated with autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT). METHODS: A total of 96 cases of high-risk refractory lymphoma received auto-PBHSCT were selected. The total survival rate after the treatment was analyzed by using Kaplan-Meier curve and long rank test, and the prognosis-related factors were analyzed by univariate analysis and COX regression analysis. RESULTS: The median survival time of 96 patients was 30.67 months, and the overall survival rate of 3 and 5 years after treatment was 81.25% and 71.88% respectively. Univariate analysis showed that the patients with high lactate dehydrogenase(LDH) level (>245 U/L), 3-5 scores of international prognostic index(IPI), hepatitis B virus (HBV) infection, high expression of Ki-67 (≥65%) and bone marrow infiltration had lower survival rate (P<0.05). COX regression analysis showed that the complete remission wasn't reached before auto-PBHSCT and the consolidation therapy was not carried out after auto-PBHSCT, both of them were the risk factors affecting the prognosis (OR=0.46, 0.12, 95% CI: 0.22-0.95, 0.02-0.82, P<0.05). CONCLUSION: Auto-PBHSCT in the treatment of patients with high-risk refractory lymphoma can significantly improve the survival status and prognosis, and the consolidotion therapy should be performed after auto-PBHSCT so as to further improve the long-term survival rate and prolong the survival time.